OrbusNeich Medical Group Holdings Limited (“OrbusNeich” or the “Group”; stock code: 6929), a multinational medical device company specializing in interventional devices for percutaneous coronary intervention (“PCI”) and percutaneous transluminal angioplasty…
– Sharing Cutting-Edge Innovation in Surgical Robotics Cornerstone Robotics Limited, a leading innovator in surgical robotics based in Hong Kong, today announced that company management will present at the 2nd…
Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaboration agreement with Travere Therapeutics, Inc. (NASDAQ: TVTX) for the development and commercialization of civorebrutinib (also…
Southeast Asia’s Only Hospital Network with Two Hospitals Receiving Distinction Siloam International Hospitals has again been recognised at the highest level with two of its hospitals receiving Magnet® with Distinction…
Avantor, a leading global provider of mission-critical products and services to the life sciences and advanced technology industries,announced today it has been appointed the exclusive distributor of Sartorius Filter Papers…
On June 25, CanSino Biologics Inc. (SSE: 688185, HKEX: 06185) announced that the Company’s ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the “MCV4”, trade name: Menhycia(R)) has recently received the drug…
On June 26, 2026, Beijing Tong Ren Tang Healthcare Investment Co., Ltd. (“Tong Ren Tang Healthcare”) stands on the eve of its Hong Kong listing. Backed by the 357-year-old time-honored…
June 26, 2026, Everest Medicines today announced that China’s National Medical Products Administration (NMPA) accepted the Biologics License Application (BLA) for LEROCHOL(R) (lerodalcibep), a third-generation PCSK9 inhibitor, for subcutaneous use…
Recently, Singapore’s sovereign wealth fund GIC updated its shareholding data for Ascletis Pharma Inc. -B (01672.HK) once again, marking its third Disclosure of Interests filing in the company this year.…
Everest Medicines (HKEX 1952.HK) announced that Everest Medicines and Hainan Herui have entered into a commercialization collaboration relating to Hainan Herui’s budesonide enteric capsules, which were approved by the National…
– Profit Attributable to Shareholders Increases to HK$301.6 Million – While Revenue Holds Firm at HK$1.57 Billion – Resilient Performance across Core Therapeutic Areas – amid Normalising Seasonal Demand KEY…
– Delivers Resilient Performance with Revenue Growth of 6.7% – Profit Attributable to Shareholders Increases 1.9% despite Increased Strategic Investment – Flagship Brands Continue to Drive Growth and Market Leadership…
China Medical System Holdings Limited (867.HK/8A8.SG) (CMS, or the Group) is pleased to announce that, the New Drug Application for Silevimig Injection (GR1801, the Product), a Class 1 therapeutic biological…
Group sharpens focus on aesthetics retail under the CEO’s first initiative, a proposed entry into the Xiamen aesthetic clinic market Accrelist Ltd. (“Accrelist” or the “Company”, together with its subsidiaries,…
Everest Medicines (HKEX 1952.HK)announced that it has entered into an exclusive licensing agreement with Australia Dimerix Limited (Dimerix), for the development and commercialization of DMX-200 in Greater China (Chinese mainland,…
China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the preclinical results of its self-developed innovative INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”), have…
HONG KONG, Jun 8, 2026 – (ACN Newswire) – Everest Medicines (HKEX 1952.HK) announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals (“CORXEL”). Under the agreement,…
iHerb, a global e‑commerce platform specializing in health and wellness products, has officially launched its 2026 “618 Peak Shopping Festival.” As a brand with a 29‑year heritage, this initiative brings…
HighTide Therapeutics, Inc. (HKG: 2511), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new findings on the renoprotective effects of…
Everest Medicines (HKEX 1952.HK) announced that it has entered into a commercialization license agreement with Beijing Mabworks Biotech Co., Ltd. (Mabworks), under which the Company has obtained exclusive rights for…
